Abstract
BACKGROUND
Daphnein is the first new drug in China. In addition to the treatment of cardiovascular diseases and coronary heart disease, daphnein also has anti-inflammatory, anti-apoptosis, analgesia, and immunity-enhancing activities. Some studies have reported that daphnetin may inhibit the activities of cyclooxygenase and 5-ester oxidase and produce anti-inflammatory and anti-allergic reactions by inhibiting the synthesis of prostaglandin and leukotriene.
AIM
To explore the efficacy of daphnetin in the treatment of colitis, and observe its effect on the composition of microbiota and the balance of regulatory T cells (Treg)/helper Th17 cells (Th17).
METHODS
One hundred and eight patients with ulcerative colitis (UC) admitted to our hospital from June 2017 to November 2019 were selected and randomly divided into either a control group or an observation group, with 54 cases in each group. Both groups were given conventional Western medicine treatment, and the observation group was additionally given daphnetin. The total effective rate, Baron endoscopic score, Geboes mucosal histology score, modified Mayo activity index, intestinal flora distribution, Treg/Th17 balance changes [CD4+CD25+Foxp3+ Treg, interleukin-10 (IL-10), transforming growth factor β (TGF-β), CD3+CD4+IL-17A+ Th17, interleukin-17 (IL-17), and interleukin-21 (IL-21)], the simplified Chinese version of the Inflammatory Bowel Disease Quality of Life Scale (IBDQ) score, and adverse reactions of the two groups were compared.
RESULTS
The total effective rate of the observation group was 90.74%, which was higher than that of the control group (70.37%; P < 0.05). Baron endoscopy score, Geboes mucosal histology score, and modified Mayo activity index of the observation group after treatment were significantly lower than those of the control group (P < 0.05). The numbers of E. coli, Bacteroides, and Enterococcus in the observation group were significantly lower and those of Lactobacillus and Bifidobacterium were significantly higher in the observation group than in the control group (P < 0.05). CD4+CD25+Foxp3+ Treg, IL-10, and TGF-β were significantly higher and CD3+CD4+IL-17A+ Th17, IL-17, and IL-21 were significantly lower in the observation group than in the control group (P < 0.05). The scores of emotional ability, intestinal symptoms, social ability, and systemic symptoms on the IBDQ scale were significantly higher in the observation group than in the control group (P < 0.05).
CONCLUSION
Daphnetin can promote the healing of the intestinal mucosa of UC patients by modulating the microbiome composition and Treg/Th17 balance and effectively improve the patient's condition and quality of life, which is safe and reliable.
Collapse